AO 1535

Drug Profile

AO 1535

Latest Information Update: 10 Oct 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fidia Farmaceutici
  • Class Anti-inflammatories; Glycolipids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation; Skin disorders

Most Recent Events

  • 10 Oct 2003 Discontinued - Preclinical for Inflammation in Italy (unspecified route)
  • 10 Oct 2003 Discontinued - Preclinical for Skin disorders in Italy (unspecified route)
  • 02 Feb 2001 Profile reviewed but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top